02/16
Headlines

NASDAQ:CLVS

Biotech Unusual Volume: Capstone Therapeutics (OTCMKTS:CAPS), Xencor (NASDAQ:XNCR), Durata Therapeutics (NASDAQ:DRTX), Clovis Oncology (NASDAQ:CLVS)

Kristen Barton02 mins

Capstone Therapeutics Corp. (OTCMKTS:CAPS) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), today will hold a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013. Capstone Therapeutics Corp. (OTCMKTS:CAPS) stock performance was 4.00% in last session…

Read More

NASDAQ most Volatile: InterMune Inc (NASDAQ:ITMN), ACADIA Pharmaceuticals (NASDAQ:ACAD), Clovis Oncology (NASDAQ:CLVS), Synageva BioPharma (NASDAQ:GEVA)

Mark Doerr02 mins

Board of Directors of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) adopted an updated annual incentive cash compensation program for its executive officers to be effective beginning with 2014. The description of this program is set forth in Exhibit 99.1 and is incorporated herein by reference. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) dropped -6.61 percent to $26.01 Friday on volume…

Read More
FB Nasdaq FB Facebook

Biotech Stocks Touching New Highs: Clovis Oncology (NASDAQ:CLVS), Vanda Pharmaceuticals (NASDAQ:VNDA), Insys Therapeutics (NASDAQ:INSY), Albany Molecular Research (NASDAQ:AMRI)

Jason Knox02 mins

Clovis Oncology Inc. reported a fourth quarter loss of $0.92 per share after the bell Thursday, compared to the loss of $0.81 per share last year. Clovis Oncology Inc. (NASDAQ:CLVS) stock performance was 1.58% in last session and finished the day at $79.62. Traded volume was 0.00 shares in the last session and the average…

Read More